Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer
Journal of the National Comprehensive Cancer Network · 2025-01 · 23 (1)
DOI: 10.6004/jnccn.2024.7067 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025-01. Verfasst von Dustin A Deming. Beteiligte Einrichtung: 1Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health,…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a heterogeneous group of diseases comprising several molecular subtypes. Comprehensive DNA sequencing is now standard practice to identify these subtype. Until recently, KRAS mutation status in metastatic CRC was primarily used as a biomarker to predict resistance to EGFR inhibition. However, with up to 40% of CRC cases harboring KRAS mutations, therapeutic targeting of RAS has been an area of great need. The development of KRAS G12C inhibitors has led to the FDA approval of drugs for treating non–small cell lung cancer. Recently, these and other newly developed inhibitors have been investigated as monotherapies and in combination for metastatic KRAS G12C -mutant CRC. This review examines the development of these inhibitors and highlights data supporting the inclusion of sotorasib and adagrasib, in combination with either panitumumab or cetuximab, in the NCCN Guidelines for CRC for the treatment of refractory metastatic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
- 2University of Wisconsin Carbone Cancer Center, Madison, WI.
- 3Department of Oncology, McArdle Laboratory for Cancer Research, Madison, WI.
Zitieren
APA
Deming, D. A. (2025). Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network, 23(1). https://doi.org/10.6004/jnccn.2024.7067
Vancouver
Deming DA. Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network. 2025;23(1). doi:10.6004/jnccn.2024.7067
BibTeX
@article{Deming2025,
author = {Deming, Dustin A},
title = {Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2025},
volume = {23},
number = {1},
doi = {10.6004/jnccn.2024.7067}
}
EUVIMED